Olema Pharmaceuticals (OLMA) Receivables - Other (2021 - 2026)

Olema Pharmaceuticals (OLMA) has 6 years of Receivables - Other data on file, last reported at $3.3 million in Q1 2026.

• On a quarterly basis, Receivables - Other rose 72.97% year-over-year to $3.3 million in Q1 2026; TTM through Mar 2026 was $3.3 million, a 72.97% increase from a year earlier, with the FY2025 full-year figure at $3.1 million, up 47.97% from the prior year.
• Receivables - Other for Q1 2026 stood at $3.3 million, up from $3.1 million in the prior quarter.
• Over the last five years, Receivables - Other for OLMA reached as high as $3.3 million in Q1 2026 and fell as low as $221000.0 in Q2 2023.
• Historically, Receivables - Other has averaged $1.3 million across 5 years, with a median of $687000.0 in 2024.
• Across the five-year window, Receivables - Other decreased 8.32% in 2023 and jumped 271.49% in 2024, its largest moves.
• Year by year, Receivables - Other stood at $319000.0 in 2022, then jumped by 110.97% to $673000.0 in 2023, then soared by 215.01% to $2.1 million in 2024, then jumped by 47.97% to $3.1 million in 2025, then gained by 5.87% to $3.3 million in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $3.3 million in Q1 2026, $3.1 million in Q4 2025, and $2.1 million in Q3 2025.